- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Implementing CRM Learnings and Utilization of Telehealth
The panel of experts concludes by exploring the implementation of cardiometabolic risk management learnings and the utilization of telehealth in clinical practice.
EP: 1.The Impact of CRM Diseases in the US: Burden, Prevalence, and Obesity
EP: 2.Strategies for Prevention and Screening of CRM Conditions
EP: 3.The Link Between Obesity and CRM Conditions
EP: 4.Challenges in Managing Co-Morbid CRM Conditions
EP: 5.Contemporary Guidelines for CRM Conditions
EP: 6.Reasons for Low Adherence to Guidelines for CRM Conditions
EP: 7.Overcoming Barriers to Prescribing First-Line Medications for CRM Conditions
EP: 8.Educational Initiatives to Enhance Guideline Adherence in CRM
EP: 9.Addressing Gaps in CKD, T2D, and CVD Guidelines
EP: 10.Care Coordination for High-Risk CRM Patients
EP: 11.Takeaways from the UH CINEMA Program
EP: 12.Exploring the Kidney-CHAMP Study
EP: 13.Insights from the COORDINATE-Diabetes Trial
EP: 14.Coordinating Initiatives to Enhance CRM Care
EP: 15.Implementing CRM Learnings and Utilization of Telehealth
Video content above is prompted by the following:
- How can learnings from programs and studies, like those discussed today, be disseminated, scaled, and implemented at health systems across the US?
- With the rise of telehealth, healthcare has never been as accessible as it is now. What are some of the creative ways you and your healthcare organization have implemented technology to better patient care coordination? (Dr. Jhamb)
- How have you gained organization support for improved care coordination?
- What new challenges have risen because of innovative technologies?
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD
May 17th 2025Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.
Read More
Predicting Mortality Risk Using the PREVENT Equation Across Diverse Racial Groups
May 16th 2025This study validates the Predicting Risk of CVD Events (PREVENT) score across diverse racial and ethnic populations, highlighting its effectiveness in predicting cardiovascular risk and mortality, regardless of race or ethnicity.
Read More
